Screening of HIV infection: Role of molecular and immunological assays

Expert Review of Molecular Diagnostics

Volumn 6, Issue 3, 2006, Pages 399-411

  Weber, Bernard ^a  

^a Laboratoires Reunis Kutter Lieners Hastert Centre Langwies   (Luxembourg)

Author keywords

Diagnostic window; HIV antigen; HIV 1 RNA; Nucleic acid amplification test; Primary HIV infection

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NUCLEIC ACID; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

BLOOD BANK; BLOOD DONOR; COST EFFECTIVENESS ANALYSIS; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LABORATORY TEST; PHENOTYPE; PRISM; RELIABILITY; REVIEW; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; TORQUE TENO VIRUS; BLOOD; CHEMISTRY; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; ECONOMICS; GENETIC VARIABILITY; GENETICS; IMMUNOLOGICAL PROCEDURES; INCIDENCE; MASS SCREENING; METHODOLOGY; REPRODUCIBILITY; RISK; VIROLOGY;

BLOOD; BLOOD DONORS; COST-BENEFIT ANALYSIS; FALSE NEGATIVE REACTIONS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOLOGIC TESTS; INCIDENCE; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCIBILITY OF RESULTS; RISK; SENSITIVITY AND SPECIFICITY; VARIATION (GENETICS);

EID: 33745965264     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.3.399     Document Type: Review

References (72)

1. Constantine NT, Zink H. HIV testing strategies after two decades of evolution. Indian J. Med. Res. 121, 519-538 (2005). •• Very recent and complete overview on the field of HIV diagnosis with focus on rapid tests and confirmation algorithms.
2. Fiebig EW, Heldebrant CM, Smith RI, Conrad AJ, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J. Acquir. Immune Defic. Syndr. 39, 133-137 (2005). •• First publication to describe blips of low-level viremia prior to the exponential pre-ramp-up phase. These findings have a potential impact on current blood-donor screening strategies.
3. Weber B, Berger A, Rabenau H, Doerr HW. Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J. Clin. Microbiol. 40, 1420-1426 (2002). • Evaluation of the most sensitive commercially available fourth-generation assay to date, which has a unique feature whereby it can differentiate the signal of the antigen and antibody detection modules.
4. Murthy KK, Henrard DR, Eichberg JW et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 39, 688-693 (1999).
5. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339, 33-39 (1998).
6. Fiebig EW, Wright DJ, Rawal BD et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17, 1871-1879 (2003). • Classification of primary HIV infection into distinct laboratory stages and quantitative analysis of preseroconversion replication rates may facilitate the diagnosis of recent infection and stratification of patients enrolled in clinical trials.
7. Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921-929 (2000). • Cut-off of the viral load for heterosexual transmission of HIV.
8. Van Gemen B, Kievits T, Schukkink R et al. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J. Virol. Methods 43, 177-187 (1993).
9. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 102, 117-124 (1997).
10. Stekler J, Collier AC. Primary HIV infection. Curr. HIV/AIDS Rep. 2, 68-73 (2004).
11. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 40, 143-159 (2000).
12. Clark SJ, Kelen GD, Henrard DR et al. Unsuspected primary human immunodeficiency virus type 1 infection in seronegative emergency department patients. J. Infect. Dis. 170, 194-197 (1994).
13. Ly TD, Edlinger C, Vabret A. Contribution of combined detection assays of p24 antigen and anti-human immunodeficiency virus (HIV) antibodies in diagnosis of primary HIV infection by routine testing. J. Clin. Microbiol. 38, 2459-2461 (2000). • Representative study of the yield of fourth-generation HIV assays in urban centers in France.
14. Rox JM, Eis-Hübinger AM, Muller J et al. First human immunodeficiency virus-1 Group O infection in a European blood donor. Vox Sang 87, 44-45 (2004).
15. Apetrei C, Loussert-Ajaka I, Descamps D et al. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 10, 57-60 (1996).
16. Christiansen CB, Jessen TE, Nielsen C, Staun-Olsen P. False negative anti-HIV-1/HIV-2 ELISAs in acute HIV-2 infection. Vox Sang 70, 144-147 (1996).
17. Burin des Roziers N, Coste J, Courouce A, Bibollet-Ruche F, Guillard A, Nasr O. Detection of HIV-1 RNA in two consecutive blood donations screened negative for HIV antibodies. Vox Sang 75, 298-302 (1998).
18. Imagawa DT, Lee MH, Wolinsky SM et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N. Engl. J. Med. 320, 1458-1462 (1989).
19. + subtype O. J. Clin. Microbiol. 36, 580-584 (1998).
20. Ascher DP, Roberts Ch, Fowler A. Acidification modified p24 antigen capture assay in HIV seropositives. J. Aquired Immune Defic. Syndr. 5, 1080-1083 (1992).
21. Jongerius JM, Sjerps M, Cuijpers HT et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 42, 792-797 (2002).
22. Candotti D, Richetin A, Cant B et al. Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 43, 215-225 (2003).
23. Lelie PN, van Drimmelen HA, Cuypers HT et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 42, 527-536 (2002).
24. Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 89, 193-200 (2005).
25. Mison L, Seed CR, Margaritis AR, Hyland C, Australian Red Cross Blood Service Nucleic Acid Technology Study Group. Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies. Vox Sang 84, 11-19 (2003).
26. McCormick MK, Dockter J, Linnen JM, Kolk D, Wu Y, Giachetti C. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J. Clin Virol. (2006) (In Press).
27. McAuley JD, Caglioti S, Williams RC et al. Clinical significance of nondiscriminated reactive results with the Chiron Procleix HIV-1 and HCV assay. Transfusion 44, 91-96 (2004).
28. Busch MP, Glynn SA, Stramer SL et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45, 254-264 (2005).
29. Pillonel J, Laperche S, Etablissement Francais du Sang. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill. 10, 5-8 (2005).
30. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill. 10, 8-11 (2005).
31. Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A, Gruppo Italiano per lo Studio delle Malattie Trasmissibili con la Trasfusione. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill. 10, 2-4 (2005).
32. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760-768 (2004).
33. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43, 721-729 (2003).
34. Barlow KL, Tosswill JHC, Parry JV, Clewley JP. Performance of the Amplicor human immunodeficiency virus type 1 PCR and analysis of specimens with false-negative results. J. Clin. Microbiol. 35, 2846-2853 (1997).
35. Laperche S, Morel P, Deschaseaux M et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion 43, 1428-1432 (2003).
36. Roth WK, Weber H, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood bank setting. Lancet 353, 359-363 (1999).
37. Le Corfec E, Le Pont F, Tuckwell HC, Rouzioux C, Costaglioa D. Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. Transfusion 39, 1141-1144 (1999).
38. Quinn TC, Brookmeyer R, Kline R et al. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS 14, 2751-2757 (2000).
39. Ling AE, Robbins KE, Brown TM et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 284, 210-214 (2000).
40. Delwart EL, Kalmin ND, Jones TS et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 86, 171-177 (2004).
41. Assal A, Coste J, Barlet V et al. Application of molecular biology to blood transfusion safety: the nucleic acid testing. Transfus. Clin. Biol. 10, 217-226 (2003).
42. Pilcher CD, Fiscus SA, Nguyen TQ et al. Detection of acute infections during HIV testing in North Carolina. N. Engl. J. Med. 352, 1873-1883 (2005).
43. Aubuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 45, 45-51 (1997).
44. Daar ES, Little S, Pitt J et al. Diagnosis of primary HIV infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann. Intern. Med. 134, 75-77 (2001).
45. Tersmette M, Winkel I, Groenick M et al. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24 gag. Virology 171, 149-155 (1989).
46. Van den Haesevelde M, Decourt JL, Deleys RJ et al. Genomic cloning and complete sequence analysis of highly divergent African human virus isolate. J. Virol. 68, 1586-1596 (1994).
47. Maniez M, Rouzioux C, Couroucé AM. Evaluation des trousses de dépistage de l'antigène p24 du VIH. Spectra Biologie 16, 41-49 (1997).
48. Weber B. Human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J. Clin. Microbiol. 40, 4402-4403 (2002).
49. Gürtler L, Mühlbacher A, Michl U et al. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J. Virol. Methods 75, 27-38 (1998).
50. Weber B, Fall EMB, Berger A, Doerr HW. Reduction of diagnostic window by new fourth- generation human immunodeficiency virus screening assays. J. Clin. Microbiol. 36, 2235-2239 (1998). • First study to be published that demonstrated the reduction of the diagnostic window with fourth-generation HIV tests.
51. Laperche S, Maniez-Montreuil M, Couroucé AM. Screening tests combined with p24 antigen and anti-HIV antibodies in early detection of HIV-1. Transfus. Clin. Biol. 7, S18-S24 (2000).
52. Weber B, Mühlbacher A, Michl U et al. Multicenter evaluation of a new rapid automated HIV antigen detection assay. J. Virol. Methods 78, 61-70 (1999).
53. Ly TD, Martin L, Daghfal D et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J. Clin. Microbiol. 39, 3122-3128 (2001).
54. Weber B, Gurtler L, Thorstensson R et al. Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J. Clin. Microbiol. 40, 1938-1946 (2002).
55. Weber B. A new automated fourth-generation HIV screening assay with sensitive antigen detection module and high specificity. Methods Mol. Biol. 304, 245-255 (2005).
56. Couroucé, AM, Groupe de Travail Rétrovirus de la SFTS. Tests de dépistage combiné des anticorps anti-VIH et de l'antigène p24. Gazette Transfus. Sang. 155, 4-18 (1999).
57. Meier T, Knoll E, Henkes M, Enders G, Braun R. Evidence for a diagnostic window in fourth generation assays for HIV. J. Clin Virol 23, 113-116 (2001).
58. Weber B, Meier T, Enders G. Fourth generation human immunodeficiency virus (HIV) screening assays with an improved sensitivity for p24 antigen close the second diagnostic window in primary HIV infection. J. Clin Virol 25, 357-359 (2002).
59. Weber B, Thorstensson R, Tanprasert S, Schmitt U, Melchior W. Reduction of the diagnostic window in three cases of human immunodeficiency-1 subtype E primary infection with fourth-generation HIV screening assays. Vox Sang 85, 73-79 (2003). • One of the very few studies to be performed that analyzed the impact of genetic variability on the detection of primary HIV infection.
60. Sickinger E, Stieler M, Kaufman B et al. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J. Clin. Microbiol. 42, 21-29 (2004).
61. Andersson S, Asjo B, Jenum PA et al. Relevance of a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: case reports. Clin. Lab. 50, 409-413 (2004).
62. McElborough D. Importance of using an HIV Ag/Ab combined assay in a UK population at high risk of acquiring HIV infection. Commun. Dis. Public Health 7, 312-314 (2004).
63. Brust S, Duttmann H, Feldner J, Gurtler L, Thorstensson R, Simon F. Shortening of the diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test. J. Virol. Methods 90, 153-165 (2000).
64. Ly TD, Laperche S, Brennan C et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J. Virol. Methods 122, 185-194 (2004).
65. Saville RD, Constantine NT, Cleghorn FR et al. Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J. Clin. Microbiol. 39, 2518-2524 (2001).
66. Bourlet T, Pretis C, Pillet S, Lesenechal M, Piche J, Pozzetto B. Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV. J. Virol. Methods 127, 165-167 (2005).
67. Sutthent R, Gaudart N, Chokpaibulkit K, Tanliang N, Kanoksinsombath C, Chaisilwatana P. p24 antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 41, 1016-1022 (2003).
68. Roland ME, Elbeik TA, Kahn JO et al. HIV RNA testing in the context of nonoccupational postexposure prophylaxis. J. Infect. Dis. 190, 598-604 (2004).
69. Ly TD, Laperche S, Courouce AM. Early detection of human immunodeficiency virus infection using third- and fourth-generation screening assays. Eur. J. Clin. Microbiol. Infect. Dis. 20, 104-110 (2001).
70. van Binsbergen J, Siebelink A, Jacobs A et al. Improved performance of seroconversion with a 4th generation HIV antigen/antibody assay. J. Virol. Methods 82, 77-84 (1999).
71. Busch M. Serologic Techniques. 1998 Conference On The Laboratory Science Of HIV. 21-28 (1998). www.phppo.cdc.gov/mlp/pdf/labhiv/MBusch.pdf
72. US FDA: Current Licensed Establishments and Products www.fda.gov/cber/ep/ part3.htm